{"SPADE_UN_14458": {"Clinical Information": [], "Patent Information": [], "Sequence Information": {"SPADE ID": "SPADE_UN_14458", "Peptide Name": "LP-93", "Source": "Synthetic construct", "Family": "Retroviridae", "Gene": "Not found", "Sequence": "WEQKIEELLKKAEEQQKKNEEELKX", "Sequence Length": 25, "UniProt Entry": ["http://www.uniprot.org/uniprot/P03377"], "Protein Existence": "Not found", "Biological Activity": ["Antimicrobial", "Antiviral"], "Target Organism": "[Ref.30867304]HIV-1 NL4-3(X4):inhibition of virus replication in TZM-bl cells(IC50=6.27±1.26 pM);HIV-1 JR-CSF(R5):inhibition of virus replication in TZM-bl cells(IC50=6.55±1.97 pM);HIV-1 89.6(R5X4):inhibition of virus replication in TZM-bl cells(IC50=7.57±0.62pM);HIV-1 pseudovirus:inhibition of pseudovirus infection in TZM-bl cells(IC50=9.89 pM);T-20 sensitive HIV-1(NL4-3D36G):inhibition of virus infection in TZM-bl cells(IC50=0.006±0.001 nM);T-20 resistant HIV-1 NL4-3(WT,I37T,V38A,V38 M,Q40H,N43K,G36S/V38 M,I37T/N43K,V38A/N42T):inhibition of virus infection in TZM-bl cells(IC50=0.012-2.17 nM);HIV-2(ROD,ST):inhibition of virus infection in TZM-bl cells(IC50=1.244-3.514 nM);SIV(239,PBJ):inhibition of virus infection in TZM-bl cells(IC50=0.013-0.773 nM);HIV-1(1A,2B,1C,1G,1A/C,1A/E,1B/C subtype):inhibition of cell-cell fusion between HEK293T cells and TZM-bl cells(IC50=14.51pM).", "Hemolytic Activity": "No hemolysis information or data found in the reference(s) presented in this entry", "Cytotoxicity": "No cytotoxicity information or data found in the reference(s) presented in this entry", "Binding Target": "membrane", "Linear/Cyclic": "Linear", "N-terminal Modification": "Acetylation", "C-terminal Modification": "Amidation", "Stereochemistry": "L", "Structure Description": "Not found", "Formula": "C133H217N35O44", "Mass": 3139.74, "PI": 4.94, "Net Charge": -2, "Hydrophobicity": -1.944, "Half Life": "Mammalian:2.8 hourYeast:3 minE.coli:2 min", "Mechanism of action": "The peptide had extremely potent activity to block HIV envelope-mediated cell-cell fusion,showing a greatly increased potency relative to its inhibition on virus infection. Besides, it efficiently bounds to both the cellular and viral membranes to exert their antiviral activities.", "Literature": [{"Title": "Design and Characterization of Cholesterylated Peptide HIV-1/2 Fusion Inhibitors with Extremely Potent and Long-Lasting Antiviral Activity.", "Pubmed ID": "30867304", "Reference": "J Virol. 2019 May 15;93(11)e02312-18.", "Author": "Zhu Y, Chong H, Yu D, Guo Y, Zhou Y, He Y.", "URL": "http://www.ncbi.nlm.nih.gov/pubmed/?term=30867304"}], "Frequent Amino Acids": "EKL", "Absent Amino Acids": "CDFGHMOPRSTUVY", "Basic Residues": 6, "Acidic Residues": 8, "Hydrophobic Residues": 6, "Polar Residues": 11, "Positive Residues": 6, "Negative Residues": 8, "Similar Sequences": [{"SPADE_ID": "SPADE_UN_14327", "Similarity": 1.0, "Sequence": "WEQKIEELLKKAEEQQKKNEEELKK"}, {"SPADE_ID": "SPADE_UN_14329", "Similarity": 1.0, "Sequence": "WEQKIEELLKKAEEQQKKNEEE"}, {"SPADE_ID": "SPADE_UN_14330", "Similarity": 1.0, "Sequence": "WEQKIEELLKKAEEQQKKNE"}]}}}